Literature DB >> 27246371

Addition of High-Dose Cytarabine to Fludarabine-Based Conditioning for Hematopoietic Stem Cell Transplantation for Treating Fanconi Anemia Patients with Advanced Myeloid Malignancy: A Single-Center Experience and Literature Review.

Takahiro Aoki1, Katsuyoshi Koh2, Yuhachi Ikeda2, Yujin Sekinaka2, Kosuke Akiyama2, Makiko Mori2, Yuki Arakawa2, Ryoji Hanada2.   

Abstract

The complication of Fanconi anemia (FA) with acute leukemia is rare and challenging to treat because of high relapse rates, despite the improved outcome of hematopoietic stem cell transplantation with fludarabine-based conditioning for treating FA patients with hematological abnormalities. We added high-dose cytarabine to fludarabine-based conditioning to promote an enhanced antitumor effect and successfully subjected 4 patients with FA, including 3 with acute leukemia, to hematopoietic stem cell transplantation. All patients remain alive without treatment-related mortality or evidence of disease. Adding high-dose cytarabine to fludarabine-based conditioning may be tolerable and effective for treating FA patients with acute leukemia.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute leukemia; Fanconi anemia; Fludarabine-based conditioning; Hematopoietic stem cell transplantation; High-dose cytarabine

Mesh:

Substances:

Year:  2016        PMID: 27246371     DOI: 10.1016/j.bbmt.2016.05.021

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  1 in total

1.  Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma.

Authors:  Xiaoqi Wang; Kaniel Cassady; Zhongmin Zou; Xi Zhang; Yimei Feng
Journal:  Front Med (Lausanne)       Date:  2021-07-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.